Canada Markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.20-0.32 (-4.91%)
At close: 04:00PM EST
6.20 0.00 (0.00%)
After hours: 04:47PM EST
Sign in to post a message.
  • w
    wallstreetboss
    (SCPH) $4.10--NDA resubmissin for Blockbuster Product expected during Q1 with potential FDA approval in Q3 =1000% opp...check out the presentation below :
    https://scpharmaceuticalsinc.gcs-web.com/static-files/a9b86589-737f-4ba5-84e7-5fba2b221d1f

    ###
  • M
    MAGA
    My average cost is $10. I really don't know ALLK will have any chance to come back to $15 - $20. Do you think so?
  • L
    Leo
    The decision was made to milk shorts. The time is right.
  • b
    brian
    The Biotech market is littered with former high flyers that are now low single digit stocks, Look at the charts on BLUE, WVE, SLDB to name a few. All had failed trials and have continued a steady path down to low single digit. If ALLK had a pipe of drugs, I'd feel confident in the potential, but they have nothing in the pipe but a lot of cash and an ugly burn rate. I see this stock dropping into the 6's, 5's and lower. Any potential will take 18-24 months or longer. Just my two cents for those looking for a turn around. Any movement up is an opportunity to cut your losses.
  • a
    arroundthecorner
    Total Cash Per Share (mrq) 9.31
  • L
    Leo
    Institutions started to accumulate. Good.
  • B
    Bob
    If we do not receive any positive news, this will continue in a downward spiral!!!
  • Z
    Zsolt
    They have enough cash for 2,5 years so they do not need to dilute, still a gamble as all biotech but with fair risk-reward ratio, I am in.
  • K
    Krimo
    You can short it, You can tell me how bad this is, You can jump from one stock to an other, You can buy high and sell low. But I am here for long the time, not selling under $78/share
  • #
    #Mike@
    Important patent granted Dec 21, 2021…

    Patents Assigned to ALLAKOS INC.
    Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis
    Patent number: 11203638
    Abstract: The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: December 21, 2021
    Assignee: ALLAKOS INC.
    Inventors: Christopher Robert Bebbington, Bradford Andrew Youngblood, Nenad Tomasevic
  • R
    RJ
    at 4:47pm EST, someone snagged 269k shares... hmmmm...
  • I
    I
    I believe some people like Robert don't see the facts. The price was above $85 for 3 years before Wednesday news. Then it plunged to 8.5 in one session. The findings were surprising to all. It was not pumping as you may think. Pumping would not continue for three years. The fundamentals are excellent, and the company have three other programs that will continue. The company is very hopeful. The bounce back as per analysts expectations is imminent.
  • M
    Mike Fink
    Has the CEO addressed investors? What are his plans moving forward.
    This CEO has kept investors in the dark with very little news flow all along.
  • W
    Whistleblower
    with one drug powering their pipeline and that drug now a lost cause.
    what are the options?
    Sept 31st they have 505mm cash
    Dec 31st they likely to have 450mm cash (Burn rate 55 to 60mm)
    they will need another 3 to 6 months to stabilize and move to a new target if lucky.

    meanwhile they have a new lease starting April 2022 at 90m a year.

    what price target should we expect?
  • S
    SamiJ
    Now the trading at share book value! and three ongoing promising projects. I believe the risk of further drop is not much. It depends mainly on big holders action on this stock.
    If the price drops, I believe the minimum near future price will be $8 but if it goes up, the probability that it will double is more logical.
  • A
    AB
    ALLK currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term.
  • #
    #Mike@
    The fiscal year is almost at its end 😎
    According to the wash sale rule, losses can be claimed only if the same stock is not bought within the next 30 days…so where to invest in the meantime? Here!
    Hence: we will have a lot of NEW INVESTORS here soon … 😎👍🚀
    And others - mainly institutional investors - will be re-joining within the next 33 days …
    Happy New Year!
  • #
    #Mike@
    The drug does what it intends to do. AK002 is extremely effective at depleting eos and mast cells. There is nothing like this in the market, and: strong patents are in place and granted. Expect more clarity very soon on what happened in phase 3, which will bring confidence back…Good cash reserves. Excellent prospects 🙏🚀😎
  • M
    Mike Fink
    still waiting like always for the CEO to say something. Who know what is going on internally??
  • k
    kareen
    Here is the Mystery and I would like the CEO to explain the results so that we can all make a qualified choice as to if this is a good investment or not.

    Mystery

    The latest data come from two trials: the phase 3 Enigma 2 study in patients with eosinophilic gastritis and/or eosinophilic duodenitis, and Kryptos, a phase 2/3 trial in eosinophilic oesophagitis. These disorders are characterised by eosinophilic infiltration of the gastrointestinal tract, as well as gastrointestinal symptoms varying from dyspepsia and obstruction to diarrhoea and ascites.

    The trials were aptly named: their results are mysterious to say the least. Lirentelimab significantly reduced eosinophil counts in the areas of the GI tract the studies were targeting, but failed to make a dent in symptoms as reported by patients.

    How is this possible?